Eosinophilic Leukemia Panel - FISH for PDGFRA, PDGFRB, and FGFR1
The Eosinophilic Leukemia Panel with FISH (Fluorescence In Situ Hybridization) for PDGFRA, PDGFRB, and FGFR1 is a specialized diagnostic test that aims to identify genetic abnormalities associated with eosinophilic leukemia. Eosinophilic leukemia is a rare form of blood cancer where the bone marrow produces too many eosinophils, a type of white blood cell that helps fight infections and plays a role in allergic reactions. In this condition, the eosinophils are abnormal and can accumulate in the blood and various organs, causing damage.
The panel looks for abnormalities in the PDGFRA, PDGFRB, and FGFR1 genes, which are often associated with eosinophilic leukemia. Identifying these genetic changes can be crucial for diagnosis, selecting appropriate treatment, and monitoring the disease.
Test NameEosinophilic Leukemia Panel - FISH for PDGFRA, PDGFRB, and FGFR1
Sample TypeBlood/Bone Marrow
Preparations RequiredNo special preparation is required for this test. However, it is always a good practice to inform your doctor of any medications, vitamins, or supplements you are taking.
Report Time5 days
What is FISH and how does it help in diagnosing eosinophilic leukemia?
Fluorescence In Situ Hybridization (FISH) is a molecular technique that uses fluorescent probes to detect specific DNA sequences in cells. In the context of eosinophilic leukemia, it helps in identifying genetic changes in PDGFRA, PDGFRB, and FGFR1 genes which are commonly associated with this disease.
Why is it important to detect genetic changes in eosinophilic leukemia?
Detecting genetic changes can help in confirming the diagnosis, determining the prognosis, and guiding treatment decisions. Some genetic changes may be associated with sensitivity or resistance to certain therapies.
Home Sample Collection Process
1
Book your convenient slot
2
Sample Collection by Phlebotomist
3
Reporting of the sample at lab
4
Download Reports
Frequently Asked Questions
A sample of blood or bone marrow is collected. For blood, a regular blood draw from the arm is performed. For bone marrow, a special needle is inserted into the bone to withdraw marrow.
These genes are involved in cell growth and division. Changes in these genes can lead to the uncontrolled growth of eosinophils, contributing to the development of eosinophilic leukemia.
If genetic abnormalities are detected, it is essential to consult with your doctor, who will guide you through the next steps, which may include further testing, monitoring, or treatment options.
The blood draw is generally safe with minimal risks. Bone marrow aspiration carries risks like infection and bleeding, but these are generally low when performed by an experienced medical professional.
Yes, this test can be used to monitor the progression of the disease and to check the effectiveness of treatment by looking for changes in the levels of abnormal cells.
Yes, there are treatments available which include chemotherapy, targeted therapy, and sometimes stem cell transplantation. The choice of treatment depends on various factors including the type of genetic abnormalities present.
Yes, certain genetic changes are associated with a poorer prognosis, while others may be associated with a better response to treatment. Understanding the genetic makeup of the leukemia cells can provide valuable information regarding the likely course of the disease.
This test is not performed routinely and is generally ordered when eosinophilic leukemia is suspected based on clinical symptoms and initial blood tests.
The possibility of a cure depends on various factors including the stage of the disease, genetic makeup of the leukemia cells, and the patient’s overall health. Some patients achieve long-term remission with treatment.
No, this test does not replace the need for a bone marrow biopsy. It is often used in conjunction with a bone marrow biopsy for a comprehensive evaluation.
A hematologist is a doctor who specializes in blood disorders, including leukemia. They are instrumental in diagnosing, treating, and monitoring patients with eosinophilic leukemia.
Currently, there is no known way to prevent eosinophilic leukemia as the exact cause is not known.
Coverage for this test depends on your insurance plan. It is recommended to check with your insurance provider regarding coverage.
The Eosinophilic Leukemia Panel - FISH for PDGFRA, PDGFRB, and FGFR1 is a valuable diagnostic tool that aids in the identification of genetic abnormalities associated with eosinophilic leukemia. This information can be critical in guiding treatment decisions and monitoring the course of the disease. If you or a loved one have been diagnosed with or are suspected of having eosinophilic leukemia, it's important to discuss with a doctor the benefits of undergoing this testing.
Eosinophilic leukemia panel - FISH for PDGFRA, PDGFRB and FGFR1
